ITF 2357 inhibits class I and class II histone deacetylases (maize HDACs: HD2, HD-1B, and HD-1A with IC50s = 7.5-16 nM) and reduces the production of several pro-inflammatory cytokines including TNFα, IL-1α, and IL-1β (IC50s = 10-22 nM). ITF 2357 also has activity against cells expressing janus kinase 2 (JAK2)V617F (IC50s = 1-10 nM), a mutated form of the JAK2 enzyme that is implicated in the pathophysiology of many myeloproliferative diseases, including polycythaemia vera.
